Abstract: The present invention discloses a nanocochleate formulation and a method for preparing the nanocochleate formulation. The formulation provides a pharmaceutical composition based on a nanocochleate consisting of phospholipids of phosphatidylserine (PS), cholesterol, at least one drug, and a surfactant, which are consequently stabilized in presence of cations like cerium from degradation agents. The formulation is homogenized to produce nanocochleate containing the drug. The formulation using nanocochleate containing phosphatidylserine and drug such as alendronate or vitamin D as an anti-osteoporotic agent provide significant protection against bone loss, which would need a minimal or even without any drug to improve osteoporosis in osteoporotic animals.

Abstract: A liposomal formulation for targeting immunotherapy, with synergistic effect in the case of encapsulating an immunosuppressive drug, such as Cyclosporine A, and the method of preparing the same. The reduced toxicity and significant reduction of Delayed-Type Hypersensitivity DTH) due to extremely reduced dosage, potential therapeutic value in control of chronic transplant rejection, allergies and certain autoimmune diseases, and increased efficacy are some of numerous and significant benefits of the present invention.